152 results about "Viral culture" patented technology

The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.

The invention relates to an ST cell adapting to full-suspension culture, and an application in vaccine virus culturing, and belongs to biotechnical field. The ST cell adapting to full-suspension culture is named as a swine testicle cell suspension adaptation strain ST-2014S, and is preserved in China Center for Type Culture Collection on May 13, 2015 with the preservation number of CCTCC C201567. The invention also discloses a method for culturing a vaccine virus through using the full-suspension adaptation ST cell. Compared with vaccine viruses in the prior art, the full-suspension adaptation ST cell cultured vaccine virus has the advantages of high automation degree, no need of vector intervention, realization of suspension culture in a serum-free or low-serum medium, meeting of large-scale industrial requirements of virus culture, development of a large-scale production method meeting GMP production technology requirements, and very good industrial application prospect.

Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMIC® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).

The invention provides a method for cultivating ginger-free viruses and cultivating virus-free seedlings by means of propagating and rooting synchronously, which comprises the steps of: (1) taking the tender bud which is germinated from the root and the stem of the ginger as an explant, and disinfecting the explant; (2) thermally treating the disinfected explant, and performing the tissue culture on the stem tip in an MS (mass spectrometry) culture medium to obtain the virus-free seedlings; (3) putting the virus-free seedlings obtained in the step (2) in the MS culture medium to perform the synchronous cultivation by means of propagating and rooting to obtain the monoclonal seedlings with roots; and (4) refining the monoclonal seedlings, transplanting the refined monoclonal seedlings into a seedling bed for growing for one month, and transplanting the grown monoclonal seedlings into a large field. The cultivation method is high-efficiency and simple, so that various viruses in the ginger can be effectively removed, and the quality of the ginger can be improved.

The invention discloses a production method of a canine parvovirus inactivated vaccine by utilizing a bioreactor. The production method comprises the following steps: (1) culturing a vaccine producing cell by applying a microcarrier and chip carrier system of the bioreactor; (2) vaccinating a canine parvovirus and performing virus multiplication culture; (3) harvesting virus culture fluid; and (4) inactivating the virus fluid with BEI (binary ethyleneimine), and adding adjuvant to prepare the vaccine. The canine parvovirus inactivated vaccine has the advantages of high density of cultured cell, high virus titer, uniform and stable quality, controllable process and high production efficiency, and the defects of large difference among product batches, low antigen content and low production efficiency in a conventional spinner bottle or chick embryo production process can be overcome.

Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.

The invention relates to a SARS-CoV-2 inactivated vaccine and a preparation method of the vaccine. The preparation method comprises the following steps: step (1) recovery and large-scale culture of Vero cells; step (2) inoculation of working seeds, batch of virus seeds, virus culture and one-time harvest virus liquid, namely, the virus harvest liquid; step (3) obtaining an inactivated virus concentrated solution after a first virus inactivation, concentration and a second virus inactivation; step (4) obtaining a vaccine stock solution after purifying the inactivated virus concentrated solution; and step (5) preparation of semi-finished product and sub-package after the stock solution is verified to be qualified.

The invention relates to the field of veterinary biological products and particularly relates to a preparation method of a mink canine distemper virus live vaccine. The method comprises the following steps: inoculating a bioreactor with sensitive cells for vaccine preparation, and culturing by using a micro-carrier; after the sensitive cells are cultured by over 50% and grow into a dense single layer, inoculating the bioreactor with canine distemper virus for enrichment culture; harvesting the virus culture liquid and micro-carrier; performing freeze-thawing and removing the micro-carrier and cell debris to obtain virus liquid; and blending the virus liquid to obtain the vaccine. By improving the reaction conditions of each step and optimizing the production flow, the method provided by the invention realizes the technical effects of short production cycle, high virus titer, stable product quality, increased production efficiency and low side effect.

The invention relates to the field of cell culture, in particular to an MDCK cell line, a method for duplicating viruses and application of the method. The cell line is preserved in China Center for Type Culture Collection, the preservation number is CCTCC NO: C201857, and the preservation time is February 10, 2018. The MDCK cell line provided by the invention is not only suitable for the full-suspension culture, but also can adopt animal-source-free serum culture medium to culture, so that the pollution risk of an external source in the virus culture or vaccine production can be reduced.

Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.

The invention relates to a method for amplifying porcine circovirus type 2 by applying a bioreactor and a flaky vector, and belongs to the technical field of biological products. The method comprises the following steps: (1) seed cell preparation; (2) bioreactor preparation; (3) PK-15 cell suspension culture; (4) PK-15 cell suspension virus culture; (5) cell suspension virus culture and continuous harvesting; and (6) virus liquid culture period and harvest yield. The method disclosed by the invention exceeds multiple technical bottlenecks of a spinner bottle production process and provides a process which obtains high-titer porcine circovirus type 2 (PCV2) virus liquid with high efficiency, sustainability and large-scale production by carrying out suspension culture on a PK15 cell by utilizing the flaky vector.

The invention relates to a method for suspension culture of Newcastle disease virus (NDV) by using a full-suspension passage cell line. The method comprises the following steps: inoculating the full-suspension EB66 cell line having a growth density of 8*10<6> cells/mL to 16*10<6> cells/mL with the NDV by using a two-stage culture method, continuously culturing after the virus is inoculated, and sampling every 12 hours so as to determine the EID50 of the virus; harvesting the virus when the titer of the virus is maximum, and storing the harvested virus so as to complete the culture of the NDV.The method adopts the duck embryonic stem cell EB66 passage cell line to culture the chicken NDV, thus effectively improving the titer and purity of the obtained virus, further enabling produced vaccines to have higher quality, and lowering the production cost.

The invention relates to a Vero-pAPN (Porcine Aminopeptidase N) cell line. An adopted construction method is a slow virus mediating method. Compared with a Vero cell line which is constructed by parental Vero cells and an instant transfer mode and is used for expressing pAPN, cells of the cell line disclosed by the invention can stably express APN protein at a higher level and improve the PEDV (porcine epidemic diarrhea virus) breeding titer, and become host cells more suitable for multiplication of PEDV. The cells can be applied to subsequent virus culture, separation and purification, and provide host raw materials for preparation of vaccines.

The invention discloses a vero E6 cell strain adapting to full-suspension culture, the vero E6 cell strain is named as vero E6-s, and is preserved in China Center for Type Culture Collection, the preservation number is CCTCC2017101, the vero E6 cell strain is classified and named as Vero cell suspension adaptive strain VeroE6-S, and the preservation date is June 29, 2017. Compared with the prior art, the vero E6 cell strain adapting to the full-suspension culture has high degree of automation for culture of vaccine viruses, can be suspended and cultured in a serum-free or low-serum medium without carrier intervention, and solves large-scale industrialization requirements of virus cultivation, a large-scale production method meeting GMP production technology requirements can be developed, and the large-scale production method has a good prospect of industrialization.

The invention relates to the technical field of biology, in particular to a method for producing a human diploid cell encephalitis B inactivated vaccine. The method sequentially comprises the following steps of: resuscitating and subculturing a human diploid cell strain; culturing the human diploid cell strain by using a multi-stage bioreactor; inoculating an encephalitis B virus strain, and performing virus multiplication culture; harvesting a virus culture solution; and inactivating the virus culture solution, performing ultrafiltration, purifying, adding a glycoprotein protective agent, and preparing the vaccine. Human diploid cells are used as a cell matrix, so that the vaccine is safe and is free from exogenous factor pollution; the human diploid cells are cultured by the bioreactor through stage-by-stage linear amplification, so that the large-scale production of the vaccine with low cost, high quality, safety and stability is easy to implement; and the titer of the virus harvested solution is subjected to sampling inspection every day, so that the high expression of the harvested virus culture is ensured, and production quality is ensured.

The present invention provides one kind of fast and sensitive method for detecting virus infection titer of attenuated live hepatitis A vaccine. The method determines the existence of the virus via detecting the negative brand RNA intermediate of marker appearing during duplicating hepatitis A virus, and is superior to available inverse transcription PCR method and cell culturing method. The method has culture period shortened to 8 days, short detection period, no need of replacing maintaining liquid, less contamination possibility, less cell post-treating steps, high work efficiency and capacity of providing virus heredity information via sequencing the PCR product.

The invention provides an infectious bursal disease virus Vero cell-adapted strain and belongs to the field of bioengineering. The related infectious bursal disease virus Vero cell-adapted strain is named Ck /Jiangsu/ NJ-23/2008 and has a collection No. of CGMCCNO.8852. The infectious bursal disease virus Vero cell-adapted strain which can efficiently multiply on serum-free cultured Vero cell is finally obtained through wild strain separation, chick embryo passage, Vero cell passage adaption; the infectious bursal disease virus Vero cell-adapted strain is subjected to continuous passage culture on the serum-free cultured Vero cell and TCID50 can be kept to be higher than 108.5/mL. Virus culture solution is inactivated and prepared into oil emulsion; after the prepared oil emulsion is used to immunize chicken, detection proves that the prepared oil emulsion has good immunogenicity. The infectious bursal disease virus (IBDV) strain and the production process thereof are simple, safe and efficient and suitable for industrial culture.

The invention relates to a method for preparing swine fever live vaccines, and belongs to the field of biotechnology. The method for preparing the swine fever live vaccines includes the following steps: (1) cell inoculation, (2) culturing of cells used for vaccine preparation, (3) virus inoculation, (4) virus culture and harvest, and (5) vaccine preparation. Cells used for vaccine preparation are screened, adaptability between the cells and virus is strengthened, a riptide perfusion type bioreactor culture system is used for improving multiplication titer and harvest yield of the virus, and a whole production process does not involve other biosafety and public health problems and is suitable for large scale production.

The invention provides a method of utilizing a stirred bioreactor to produce an infectious Bursal disease virus. Bioreactor microcarrier cell culture technology is used to replace conventional roller bottle culture, so that the problems of low production efficiency, unstable product quality and low virus titer can be solved. On this basis, biological characteristics of the infectious Bursal disease virus and DF1 cells are combined, and proper conditions are matched from the perspectives of microcarrier adding amount, cell inoculation density, virus inoculation amount, cell density during virus inoculation, virus collection time and reactor operation parameters, so that virus culture efficiency is improved remarkably, and unit culture titer is improved by 10-100 times. In addition, compared with roller bottle culture, the method utilizing the bioreactor has the advantages that culture scale is large, and parameter control is comprehensive, so that systematic risk of being polluted is lowered, quality stability is improved, and the method has a wide application prospect.